Digiliti Money (OTCMKTS: DGLT) and Lion Biotechnologies (NASDAQ:IOVA) are both small-cap business services companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.

Valuation & Earnings

This table compares Digiliti Money and Lion Biotechnologies’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Digiliti Money $7.97 million 0.27 -$15.16 million N/A N/A
Lion Biotechnologies N/A N/A -$52.89 million ($1.31) -6.34

Digiliti Money has higher revenue and earnings than Lion Biotechnologies.

Profitability

This table compares Digiliti Money and Lion Biotechnologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Digiliti Money -147.73% N/A -199.21%
Lion Biotechnologies N/A -53.59% -51.25%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Digiliti Money and Lion Biotechnologies, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Digiliti Money 0 0 1 0 3.00
Lion Biotechnologies 0 0 10 0 3.00

Digiliti Money presently has a consensus price target of $6.00, suggesting a potential upside of 2,627.27%. Lion Biotechnologies has a consensus price target of $15.31, suggesting a potential upside of 84.49%. Given Digiliti Money’s higher probable upside, analysts clearly believe Digiliti Money is more favorable than Lion Biotechnologies.

Insider and Institutional Ownership

9.3% of Digiliti Money shares are held by institutional investors. Comparatively, 65.6% of Lion Biotechnologies shares are held by institutional investors. 50.9% of Digiliti Money shares are held by company insiders. Comparatively, 13.2% of Lion Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Digiliti Money beats Lion Biotechnologies on 5 of the 9 factors compared between the two stocks.

Digiliti Money Company Profile

Digiliti Money Group, Inc., formerly Digiliti Money, Inc., is a technology solutions and services provider to the financial services industry. The Company’s solutions and services enable its clients, such as banks, credit unions and alternative financial services providers (AFS) to offer their customers remote deposit capture (RDC) and prepaid mobile money technologies and related services. It offers RDC products for businesses and consumers; mobile money management products for consumers, and training and support services for its financial services industry customers. The RDC products are offered to banks and credit unions in the United States, Canada and Latin America. Its mobile money management products are offered to traditional financial institutions (FIs), as well as AFS in the United States, Canada and Latin America. These FIs and AFS providers include banks, credit unions, prepaid card issuers, check cashers and payday lenders.

Lion Biotechnologies Company Profile

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

Receive News & Ratings for Digiliti Money Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digiliti Money and related companies with MarketBeat.com's FREE daily email newsletter.